Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations

Human Reproduction

Volumn 12, Issue 11, 1997, Pages 2379-2384

  Duijkers, I J M ^a,b,d   Klipping, C ^a   Mulders, T M T ^c   Out, H J ^c   Coelingh Bennink, H J T ^c   Vemer, H M ^b,c  

^a Dinox Medical Investigations   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NV ORGANON   (Netherlands)

^d Medical Investigations   (Netherlands)

Author keywords

FSW; Gonadotrophin; Pharmacodynamics; Pharmacokinetics; Subcutaneous

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL PLUS LYNESTRENOL; FOLLITROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; SERIC GONADOTROPIN; UNCLASSIFIED DRUG; UROFOLLITROPIN;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG TOLERABILITY; ECHOGRAPHY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE BLOOD LEVEL; NORMAL HUMAN; OVARY FOLLICLE DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030781074     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/12.11.2379     Document Type: Article

References (17)

1. Balasch, J., Miró, F., Burzaco, I. et al. (1995) The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum. Reprod., 10, 1678-1683.
2. Bentick, B., Shaw, R.W., Iffland, C.A. et al. (1988) A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization. Fertil. Steril., 50, 79-84.
3. Le Cotonnec, J.-Y., Porchet, H.C., Beltrami, V. et al. (1994a) Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil. Steril., 61, 669-678.
4. Le Cotonnec, J.-Y., Porchet, H.C., Beltrami, V. et al. (1994b) Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). II. Single doses and steady state pharmacokinetics. Fertil. Steril., 61, 679-686.
5. Couzinet, B., Lestrat, N., Brailly, S. et al. (1988) Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency. J. Clin. Endocrinol. Metab., 66, 552-556.
6. Daya, S., Gunby, J., Hughes, E.G. et al. (1995) Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization. Hum. Reprod., 10, 1392-1396.
7. Devroey, P., Mannaerts, B., Smitz, J. et al. (1994) Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens. Hum. Reprod., 9, 1064-1069.
8. Fleming, R., Chung, C.C., Yates., R.W.S. et al. (1996) Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Hum. Reprod., 11, 1854-1858.
9. Howles, C.M., Loumaye, E., Giroud, D. et al. (1994) Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum. Reprod., 9, 424-430.
10. Loumaye, E., Piazzi, A., Baird, D. et al. (1995) A prospective, randomized, parallel group study to determine the effective dose of recombinant human luteinizing hormone to support FSH-induced follicular development in hypogonadotrophic hypogonadal (HH) women. XIth Annual Meeting of the ESHRE, Hamburg (abstr 406).
11. Matikainen, T., Leeuw, R.de, Mannaerts, B. et al. (1994) Circulating bioactive and immunoreactive recombinant follicle stimulating hormone (Org 32489) after administration to gonadotropin-deficient subjects. Fertil. Steril., 61, 62-69.
12. Out, H.J., Schnabel, P.G., Rombout, F. et al. (1996) A bioequivalence study of two urinary follicle stimulating hormone preparations: Follegon and Metrodin. Hum. Reprod., 11, 61-63.
13. Rao, M.C., Midgley Jr, R. and Richards, J.S. (1978) Hormonal regulation of ovarian cellular proliferation. Cell, 14, 71-78.
14. Recombinant FSH Study Group (1995) Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil. Steril., 63, 77-86.
15. Richards, J.S. (1980) Maturation of ovarian follicles: actions and interactions of pituitary and ovarian hormones on follicular cell differentiation. Physiol. Rev., 60, 51-89.
16. School, D.C., Harlin, J., Shoham, Z. et al. (1994) Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women. Hum. Reprod., 9, 1237-1242.
17. Wide, L. and Hobson, B. (1986) Influence of the assay method used on the selection of the most active forms of FSH from the human pituitary. Acta Endocrinol. (Copenh.), 113, 17-22.